Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122161 | 1.00 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2122164 | 1.00 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL22929100 | 0.90 | RNASE1 (0.44) | RNASE1 | |
| SCHEMBL2148407 | 0.89 | TOP2A (0.41) | — | |
| SCHEMBL2148405 | 0.89 | TOP2A (0.41) | — | |
| SCHEMBL15061820 | 0.89 | RNASE1 (0.44) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL4729467 | 0.88 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL20810870 | 0.88 | RNASE1 (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2619370 | 0.88 | RNASE1 (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL20810838 | 0.88 | RNASE1 (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-9388464-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| US-9388464-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| EP-3002289-A1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Illumina Cambridge Limited (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20160032378-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20160032378-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| EP-2607369-B1 | Modified nucleotides for polynucleotide sequencing | ILLUMINA CAMBRIDGE LTD (GB) | 2015-09-23 | — | — | EP | disclosed |
| US-9121060-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9121060-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-8071739-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071739-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100292452-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LTD | 2010-11-18 | — | — | US | disclosed |
| US-7771973-B2 | sequencing reactions where nucleotide or nucleoside molecules modified by reversible covalent attachment of 3'-OH blocking groups thereto, are used where blocked nucleotide or nucleoside molecules are required | ILLUMINA CAMBRIDGE LIMITED (GB) | 2010-08-10 | — | — | US | disclosed |
| US-20090325172-A1 | Modified nucleotides | SOLEXA LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-7541444-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-06-02 | — | — | US | disclosed |
| US-20070166705-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292452-A1 | Modified nucleotides | ADAR, NT5C2, NSUN2 | RNASE1 124/4885LMNA 639/4885SMN1; SMN2 2619/4885 |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | RNASE1 123/4885LMNA 643/4885SMN1; SMN2 2620/4885 |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | RNASE1 124/4885LMNA 639/4885SMN1; SMN2 2619/4885 |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | RNMT, NSUN2, NSUN3 | RNASE1 177/4885LMNA 2798/4885SMN1; SMN2 1513/4885 |
| US-20070166705-A1 | Modified nucleotides | NT5C2, ADAR, DUT | RNASE1 136/4885LMNA 650/4885SMN1; SMN2 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.